NCT07156500View on ClinicalTrials.gov

A Phase 3 Study of HS-20094 in Patients With T2DM Inadequately Controlled With Diet and Exercise Alone

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

204

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

March 30, 2027

Study Completion Date

May 30, 2027

Conditions
Type 2 Diabetes
Interventions
DRUG

HS-20094 Injection

HS-20094 injected subcutaneously once weekly

DRUG

HS-20094 Placebo Injection

HS-20094 Placebo injected subcutaneously once weekly

DRUG

HS-20094 Injection

HS-20094 injected subcutaneously once weekly

DRUG

HS-20094 Placebo Injection

HS-20094 Placebo injected subcutaneously once weekly

Trial Locations (1)

Unknown

Beijing Hospital, Beijing

Sponsors
All Listed Sponsors
lead

Jiangsu Hansoh Pharmaceutical Co., Ltd.

INDUSTRY